ATE384077T1 - Stereoselektive antifibrillogene peptide - Google Patents

Stereoselektive antifibrillogene peptide

Info

Publication number
ATE384077T1
ATE384077T1 AT00926599T AT00926599T ATE384077T1 AT E384077 T1 ATE384077 T1 AT E384077T1 AT 00926599 T AT00926599 T AT 00926599T AT 00926599 T AT00926599 T AT 00926599T AT E384077 T1 ATE384077 T1 AT E384077T1
Authority
AT
Austria
Prior art keywords
peptide
peptides
antifibrilogenic
stereoselective
prot
Prior art date
Application number
AT00926599T
Other languages
German (de)
English (en)
Inventor
Robert Chalifour
Francine Gervais
Ajay Gupta
Original Assignee
Neurochem Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Int Ltd filed Critical Neurochem Int Ltd
Application granted granted Critical
Publication of ATE384077T1 publication Critical patent/ATE384077T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00926599T 1999-05-05 2000-05-04 Stereoselektive antifibrillogene peptide ATE384077T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13259299P 1999-05-05 1999-05-05

Publications (1)

Publication Number Publication Date
ATE384077T1 true ATE384077T1 (de) 2008-02-15

Family

ID=22454745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00926599T ATE384077T1 (de) 1999-05-05 2000-05-04 Stereoselektive antifibrillogene peptide

Country Status (8)

Country Link
EP (1) EP1173480B1 (enExample)
JP (1) JP2003503312A (enExample)
AT (1) ATE384077T1 (enExample)
AU (1) AU4529800A (enExample)
CA (1) CA2388092A1 (enExample)
DE (1) DE60037800D1 (enExample)
IL (1) IL146009A0 (enExample)
WO (1) WO2000068263A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6852696B2 (en) 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
BR0016022A (pt) * 1999-11-29 2002-08-06 Neurochem Inc Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
KR20080003945A (ko) 1999-12-23 2008-01-08 뉴로겜 인터내셔널 리미티드 대뇌 아밀로이드 혈관병증을 조절하는 화합물 및 방법
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
JP2004532203A (ja) * 2001-03-21 2004-10-21 ザ、ユニバーシティ、オブ、テキサス、システム グリコサミノグリカンの阻害剤
DE10117281A1 (de) * 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
GB2380998B (en) * 2001-08-03 2004-10-20 Marc Kvansakul D-amino acid peptide for security tagging
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
JP2006512417A (ja) * 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
GB0608960D0 (en) * 2006-05-05 2006-06-14 St Georges Hosp Medical School Imaging agent
MX339684B (es) 2006-10-12 2016-06-06 Bhi Ltd Partnership Metodos, compuestos, composiciones y vehiculos para suministrar el acido 3-amino-1-propanosulfonico.
WO2008050133A2 (en) * 2006-10-27 2008-05-02 Zapaloid Limited Inhibition of beta-amyloid aggregation
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
GB0716885D0 (en) * 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5804463B2 (ja) * 2012-12-27 2015-11-04 国立研究開発法人科学技術振興機構 環状ペプチド及びこれを含有する医薬
CN108350053A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β表位及其抗体
JP7448174B2 (ja) * 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
GB201613999D0 (en) 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2175083T3 (es) * 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
WO1997021728A1 (en) * 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
JP2001500852A (ja) * 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
JPH10182695A (ja) * 1996-12-27 1998-07-07 Teikoku Seiyaku Co Ltd ｇｐ１２０に対して親和性を有するペプチド

Also Published As

Publication number Publication date
WO2000068263A3 (en) 2001-05-03
WO2000068263A2 (en) 2000-11-16
EP1173480A2 (en) 2002-01-23
CA2388092A1 (en) 2000-11-16
JP2003503312A (ja) 2003-01-28
EP1173480B1 (en) 2008-01-16
DE60037800D1 (de) 2008-03-06
IL146009A0 (en) 2002-07-25
AU4529800A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
ATE384077T1 (de) Stereoselektive antifibrillogene peptide
AR014167A1 (es) UNA AMIDA PEPTíDICA OPIOIDE SINTÉTICA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE Y COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE.
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
ATE368053T1 (de) Antimikrobielle peptide
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
EP1803733A3 (en) Use of a polypeptide comprising the extracellular domains of IL-20RA and IL-20RB for the treatment of inflammation
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
EP1538157A3 (en) Isolation and use of SH3 binding peptides
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
MX2008009493A (es) Peptido novedoso y uso del mismo.
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
GB0110430D0 (en) Protein variants and uses thereof
EP0772773A4 (en) Src SH3 BINDING PEPTIDES AND METHOD FOR THEIR INSULATION AND USE
JP2006514822A5 (enExample)
WO1997044454A3 (en) Human phospholipase inhibitor
Sillard et al. Variant forms of galanin isolated from porcine brain
DE69607034D1 (de) Pcna bindende substanz
IL173969A0 (en) Use of peptides derived from the a alpha or b beta chain of human of human fibrinogen for the treatment of shock
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции
EE05139B1 (et) Peptiid, seda kodeeriv geen, reagent ja reaktiivikomplekt riketsioosi tuvastamiseks ning peptiidi sisaldav vaktsiin
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE50011068D1 (de) Fragmente des virus proteins 2 oder 3 des polyomavirus als fähren für wirkstoffe
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties